Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, 30 September 2026

Liabilities are $2.6M more than assets: shareholders’ equity is negative. What is a balance sheet?

30 September 2026 · total $7.9M

Owns

$65.4KLong-term assets
$7.9MOther short-term assets

Funded by

$10.5MOther liabilities

Debt is 0.0% of the total; liabilities are $2.6M more than assets.

It went from net cash of 35% of assets to net debt of 6% of assets since Q4 FY25.

Assets and net debt, three quartersTotal assetsNet debt (debt less cash)Net debt ÷ assets (right axis)
Assets and net debt, three quarters
Q4 FY25Q1 FY26Q2 FY26
Total assets$0.0B$0.0B$0.0B
Net debt (debt less cash)$0.0B$0.0B$0.0B
Net debt ÷ assets (right axis)−35.5%−19.0%5.7%
Sep '26 From the 10-Q filed 13 Nov Jun '26 Mar '26 Dec '25 Older periods
Total current assets
7.87 6.41 7.70 9.90
Total non-current assets
0.07 0.13 0.11 0.05
Total Assets
7.93 6.54 7.81 9.95
Total current liabilities
4.65 3.88 3.18 3.69
Total non-current liabilities
5.86 5.04 5.03 5.03
Total liabilities
10.51 8.92 8.22 8.71
Common Equity (Total)
(2.58) (2.39) (0.41) 1.23
Shareholders Equity (Total)
(2.58) (2.39) (0.41) 1.23
Total Debt
— 5.04 5.03 5.03

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 13 Nov 2026